期刊
MOLECULAR NEUROBIOLOGY
卷 47, 期 3, 页码 857-867出版社
SPRINGER
DOI: 10.1007/s12035-012-8377-3
关键词
Brain estrogen; Hormone therapy; Alzheimer's disease; BACE1; A beta deposition
资金
- Alzheimer's Association [IIRG-07-59510]
- American Health Assistance Foundation [G2006-118]
- NIH [R01AG032441, R01AG025888]
- Grants-in-Aid for Scientific Research [25461398, 23580388] Funding Source: KAKEN
Estrogens have been found to improve memory and reduce risk of dementia, although conflicting results such as failure of estrogen replacement therapy for treatment of Alzheimer's disease (AD) also has been reported. Only recently, our published human brain studies showed a depletion of brain estrogen in women with AD, while other studies have demonstrated cognitive impairment believed to be caused by inhibition of endogenous estrogen synthesis in females. To investigate whether the shortage of brain estrogen alters the sensitivity of response to estrogen replacement therapy, we have used genetic and surgical animal models to examine the response of estrogen treatment in AD neuropathology. Our studies have shown that early treatment with 17 beta-estradiol (E2) or genistein could reduce brain amyloid levels by increasing A beta clearance in both APP23 mice with genetic deficiency of aromatase (APP/Ar+/-), in which the brains contain nondetectable levels of estrogen, and in APP23 mice with an ovariectomy (APP/OVX), in which the brains still contain certain levels of estrogen. However, only APP/Ar+/- mice showed a great reduction in brain amyloid plaque formation after E2 or genistein treatment along with downregulation of beta-secretase (BACE1) mRNA and protein expression. Our results suggest that early and long-term usage of E2 and/or genistein may prevent AD pathologies in a dependent manner on endogenous brain estrogen levels in aged females.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据